Target intelligence / Profile preview

Gut microbiota and intestinal epithelial barrier

Molecular classification
Other
01

Overview

The gut microbiota and intestinal epithelial barrier represent a complex biological system rather than a single molecular target. This interface consists of a diverse community of trillions of microorganisms (microbiota) and a physical layer of epithelial cells reinforced by tight junction proteins that separate the host's internal environment from the external luminal contents (Nature Reviews Gastroenterology & Hepatology, 2019). The microbiota plays a critical role in maintaining barrier integrity by producing metabolites like short-chain fatty acids (SCFAs), which serve as the primary energy source for colonocytes and stimulate the production of antimicrobial peptides (Frontiers in Microbiology, 2021). Conversely, the epithelial barrier prevents the translocation of commensal and pathogenic bacteria into the systemic circulation, thereby preventing chronic inflammation. Dysfunction of this system, often referred to as increased intestinal permeability or "leaky gut," is a hallmark of various gastrointestinal and systemic diseases, including Inflammatory Bowel Disease (IBD) and metabolic syndrome (Cell Host & Microbe, 2020). Therapeutic interventions focus on restoring this balance through probiotics, prebiotics, and postbiotics, or by directly targeting the tight junction assembly with agents like larazotide acetate (Journal of Clinical Investigation, 2018). While not a single receptor or enzyme, the gut-barrier axis is a major focus of drug development for its ability to modulate systemic immunity and metabolic health through the regulation of microbial-host crosstalk.

Other names
Gut-intestinal barrier axisMicrobiota-epithelial crosstalkIntestinal mucosal barrierGut-barrier interface
02

Mechanism of action

Modulation of microbial composition to reduce pathobionts, enhancement of tight junction protein expression (e.g., zonula occludens-1, occludin), production of short-chain fatty acids (SCFAs) to provide energy for colonocytes, and regulation of mucosal immune cell activity to maintain tolerance.

03

Biological functions

Barrier functionImmune responseMetabolic homeostasisNutrient absorptionPathogen defenseSignal transduction
04

Disease associations

Inflammatory bowel diseaseIrritable bowel syndromeCeliac diseaseMetabolic syndromeObesityType 2 diabetesSepsisAutoimmune disease
05

Safety considerations

Risk of systemic translocation of probiotics in immunocompromised patientsPotential for inducing dysbiosis with broad-spectrum interventionsHigh inter-individual variability in microbiota compositionDifficulty in achieving long-term colonization of therapeutic strains
06

Interacting drugs

Larazotide acetate

7 more in the full profile.

07

Biomarkers

Serum zonulinFecal calprotectinSerum lipopolysaccharide (LPS)Short-chain fatty acid (SCFA) levels16S rRNA microbial profilingIntestinal fatty acid-binding protein (I-FABP)

Beyond the preview

Go deeper on Gut microbiota and intestinal epithelial barrier.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiota and intestinal epithelial barrier.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call